Revenio: The story progresses on track
Q1 results were slightly below our expectations, but the outlook is unchanged, and we think the value creator story is on track. The challenge is again the high valuation (2023e EV/EBIT above 30x) and hence the moderate expected return.
Revenio Group
39.24
38
Reduce
Accumulate
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures2023-04-28
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 97.0 | 110.8 | 129.1 |
growth-% | 23.10 % | 14.27 % | 16.46 % |
EBIT (adj.) | 30.9 | 33.4 | 39.1 |
EBIT-% (adj.) | 31.84 % | 30.13 % | 30.33 % |
EPS (adj.) | 0.86 | 0.95 | 1.14 |
Dividend | 0.36 | 0.41 | 0.55 |
Dividend % | 0.93 % | 1.58 % | 2.12 % |
P/E (adj.) | 44.64 | 27.15 | 22.65 |
EV/EBITDA | 30.64 | 18.32 | 15.28 |